Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD4054 in metastatic hormone-refractory prostate cancer with bone metastases
2004-000344-24Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zibotentan in prostate cancer (PCa) (3 arms), sponsored by AstraZeneca. Primary endpoint: Time to progression. Started May 2004; status: completed.
02
Drugs
zibotentan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2004-000344-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000344-24.